Concepts (164)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bronchiectasis | 5 | 2023 | 7 | 3.980 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 8 | 2023 | 12 | 3.630 |
Why?
|
| Lung Diseases | 5 | 2023 | 43 | 3.350 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 3 | 2023 | 3 | 1.930 |
Why?
|
| Mycobacterium avium Complex | 4 | 2023 | 4 | 1.500 |
Why?
|
| Medicare | 4 | 2023 | 214 | 1.370 |
Why?
|
| Nontuberculous Mycobacteria | 5 | 2023 | 7 | 1.270 |
Why?
|
| Anti-Bacterial Agents | 4 | 2023 | 142 | 1.210 |
Why?
|
| Drug Therapy, Combination | 3 | 2023 | 119 | 1.140 |
Why?
|
| Aged | 18 | 2024 | 6417 | 1.100 |
Why?
|
| Humans | 34 | 2024 | 18430 | 1.000 |
Why?
|
| Graft Rejection | 1 | 2024 | 5 | 0.940 |
Why?
|
| Vaccination | 5 | 2024 | 674 | 0.940 |
Why?
|
| Aged, 80 and over | 9 | 2024 | 2003 | 0.880 |
Why?
|
| United States | 10 | 2024 | 4164 | 0.880 |
Why?
|
| Rifamycins | 1 | 2023 | 1 | 0.880 |
Why?
|
| Opportunistic Infections | 1 | 2023 | 8 | 0.870 |
Why?
|
| Communicable Diseases | 1 | 2023 | 15 | 0.860 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2021 | 2 | 0.790 |
Why?
|
| Pseudomonas Infections | 1 | 2021 | 3 | 0.780 |
Why?
|
| Influenza Vaccines | 1 | 2024 | 290 | 0.770 |
Why?
|
| Influenza, Human | 1 | 2024 | 282 | 0.770 |
Why?
|
| Retrospective Studies | 11 | 2024 | 2550 | 0.730 |
Why?
|
| Male | 18 | 2024 | 10440 | 0.720 |
Why?
|
| Hospitalization | 2 | 2024 | 847 | 0.690 |
Why?
|
| Female | 20 | 2024 | 13136 | 0.680 |
Why?
|
| Retinal Vasculitis | 3 | 2014 | 3 | 0.650 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2024 | 567 | 0.640 |
Why?
|
| Adult | 17 | 2024 | 7910 | 0.550 |
Why?
|
| Rheumatic Diseases | 1 | 2015 | 2 | 0.520 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 31 | 0.510 |
Why?
|
| Middle Aged | 14 | 2024 | 8284 | 0.490 |
Why?
|
| Outpatients | 1 | 2015 | 111 | 0.480 |
Why?
|
| Disease Management | 1 | 2015 | 143 | 0.480 |
Why?
|
| Health Care Surveys | 1 | 2015 | 247 | 0.480 |
Why?
|
| Patient Satisfaction | 1 | 2015 | 232 | 0.470 |
Why?
|
| Physician-Patient Relations | 1 | 2015 | 197 | 0.450 |
Why?
|
| Visual Acuity | 2 | 2014 | 22 | 0.450 |
Why?
|
| Disinfection | 1 | 2013 | 2 | 0.450 |
Why?
|
| Ethambutol | 2 | 2023 | 2 | 0.450 |
Why?
|
| Staphylococcal Infections | 1 | 2013 | 15 | 0.450 |
Why?
|
| Skin Diseases, Infectious | 1 | 2013 | 5 | 0.450 |
Why?
|
| Soft Tissue Infections | 1 | 2013 | 10 | 0.450 |
Why?
|
| Cohort Studies | 8 | 2023 | 2672 | 0.440 |
Why?
|
| Herpes Zoster Vaccine | 2 | 2024 | 64 | 0.420 |
Why?
|
| Case-Control Studies | 4 | 2024 | 1173 | 0.410 |
Why?
|
| Herpes Zoster | 2 | 2024 | 88 | 0.400 |
Why?
|
| California | 4 | 2024 | 2365 | 0.370 |
Why?
|
| Rifampin | 2 | 2023 | 3 | 0.350 |
Why?
|
| Follow-Up Studies | 6 | 2017 | 1269 | 0.340 |
Why?
|
| Lung | 2 | 2023 | 62 | 0.340 |
Why?
|
| Adolescent | 9 | 2024 | 3798 | 0.290 |
Why?
|
| Risk Factors | 4 | 2024 | 3449 | 0.290 |
Why?
|
| Prospective Studies | 4 | 2023 | 1314 | 0.270 |
Why?
|
| Treatment Outcome | 5 | 2023 | 1296 | 0.270 |
Why?
|
| Young Adult | 7 | 2024 | 2518 | 0.270 |
Why?
|
| Urinary Tract Infections | 1 | 2024 | 21 | 0.240 |
Why?
|
| Seasons | 1 | 2024 | 105 | 0.240 |
Why?
|
| Corneal Transplantation | 1 | 2024 | 1 | 0.240 |
Why?
|
| Corneal Diseases | 1 | 2024 | 3 | 0.240 |
Why?
|
| Recurrence | 1 | 2024 | 187 | 0.240 |
Why?
|
| Clarithromycin | 1 | 2023 | 1 | 0.230 |
Why?
|
| Rifabutin | 1 | 2023 | 1 | 0.230 |
Why?
|
| Azithromycin | 1 | 2023 | 3 | 0.230 |
Why?
|
| Neuralgia, Postherpetic | 1 | 2024 | 15 | 0.230 |
Why?
|
| Societies, Medical | 1 | 2023 | 74 | 0.220 |
Why?
|
| Amikacin | 1 | 2023 | 1 | 0.220 |
Why?
|
| Macrolides | 1 | 2023 | 8 | 0.220 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2023 | 15 | 0.220 |
Why?
|
| Odds Ratio | 1 | 2024 | 701 | 0.200 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2021 | 2 | 0.200 |
Why?
|
| Practice Guidelines as Topic | 1 | 2023 | 333 | 0.190 |
Why?
|
| Rheumatology | 1 | 2021 | 8 | 0.190 |
Why?
|
| Sex Factors | 2 | 2019 | 661 | 0.170 |
Why?
|
| Electronic Health Records | 1 | 2024 | 747 | 0.160 |
Why?
|
| Immunosuppressive Agents | 2 | 2014 | 22 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 131 | 0.130 |
Why?
|
| Respiratory Tract Infections | 1 | 2016 | 54 | 0.130 |
Why?
|
| Oregon | 3 | 2024 | 222 | 0.130 |
Why?
|
| Linezolid | 1 | 2015 | 1 | 0.130 |
Why?
|
| Drug Tolerance | 1 | 2015 | 4 | 0.130 |
Why?
|
| Minocycline | 1 | 2014 | 1 | 0.120 |
Why?
|
| Granuloma Annulare | 1 | 2014 | 1 | 0.120 |
Why?
|
| Ofloxacin | 1 | 2014 | 4 | 0.120 |
Why?
|
| Child, Preschool | 3 | 2015 | 1478 | 0.120 |
Why?
|
| Epiretinal Membrane | 1 | 2014 | 1 | 0.120 |
Why?
|
| Retinal Hemorrhage | 1 | 2014 | 2 | 0.120 |
Why?
|
| Retinal Neovascularization | 1 | 2014 | 2 | 0.120 |
Why?
|
| Prognosis | 2 | 2014 | 624 | 0.120 |
Why?
|
| Child | 4 | 2015 | 2571 | 0.120 |
Why?
|
| Carrier State | 1 | 2013 | 8 | 0.110 |
Why?
|
| Staphylococcus aureus | 1 | 2013 | 6 | 0.110 |
Why?
|
| Secondary Prevention | 1 | 2013 | 52 | 0.110 |
Why?
|
| Cross Infection | 1 | 2013 | 28 | 0.110 |
Why?
|
| Herpesvirus 3, Human | 2 | 2024 | 49 | 0.110 |
Why?
|
| Pancreatic Pseudocyst | 1 | 2012 | 1 | 0.110 |
Why?
|
| Drainage | 1 | 2012 | 4 | 0.110 |
Why?
|
| Stents | 1 | 2012 | 11 | 0.110 |
Why?
|
| Optic Neuritis | 1 | 2012 | 4 | 0.110 |
Why?
|
| Pancreatic Ducts | 1 | 2012 | 6 | 0.110 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2012 | 8 | 0.110 |
Why?
|
| Antirheumatic Agents | 1 | 2012 | 13 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 28 | 0.110 |
Why?
|
| Systemic Vasculitis | 1 | 2011 | 1 | 0.100 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 1360 | 0.100 |
Why?
|
| Gonadal Hormones | 1 | 2011 | 1 | 0.100 |
Why?
|
| Octodon | 1 | 2011 | 1 | 0.100 |
Why?
|
| Sexual Maturation | 1 | 2011 | 8 | 0.100 |
Why?
|
| Circadian Rhythm | 1 | 2011 | 17 | 0.090 |
Why?
|
| HIV Infections | 1 | 2017 | 695 | 0.090 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 743 | 0.090 |
Why?
|
| Pandemics | 2 | 2024 | 292 | 0.090 |
Why?
|
| Time Factors | 3 | 2016 | 1136 | 0.070 |
Why?
|
| Administration, Oral | 2 | 2015 | 86 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2015 | 100 | 0.060 |
Why?
|
| Immunoglobulin G | 2 | 2016 | 29 | 0.060 |
Why?
|
| Universities | 1 | 2024 | 15 | 0.060 |
Why?
|
| Vaccines, Synthetic | 1 | 2024 | 43 | 0.060 |
Why?
|
| China | 1 | 2024 | 130 | 0.060 |
Why?
|
| Vaccines, Combined | 1 | 2024 | 91 | 0.060 |
Why?
|
| Cooperative Behavior | 1 | 2024 | 102 | 0.060 |
Why?
|
| Public Health | 1 | 2024 | 82 | 0.060 |
Why?
|
| Animals | 2 | 2016 | 261 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2023 | 80 | 0.050 |
Why?
|
| Masks | 1 | 2021 | 5 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2017 | 178 | 0.030 |
Why?
|
| Viral Load | 1 | 2017 | 135 | 0.030 |
Why?
|
| Cause of Death | 1 | 2017 | 185 | 0.030 |
Why?
|
| Bacterial Load | 1 | 2016 | 3 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2016 | 6 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2016 | 4 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2016 | 8 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2016 | 20 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2016 | 8 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 19 | 0.030 |
Why?
|
| Antibodies, Bacterial | 1 | 2016 | 38 | 0.030 |
Why?
|
| Cytokines | 1 | 2016 | 30 | 0.030 |
Why?
|
| Biopsy | 1 | 2016 | 75 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 131 | 0.030 |
Why?
|
| Remission Induction | 1 | 2014 | 25 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 208 | 0.030 |
Why?
|
| Age Factors | 1 | 2017 | 965 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2015 | 253 | 0.030 |
Why?
|
| Fluorescein Angiography | 1 | 2014 | 7 | 0.030 |
Why?
|
| Prednisone | 1 | 2014 | 5 | 0.030 |
Why?
|
| Vision Disorders | 1 | 2014 | 18 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2014 | 21 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2012 | 4 | 0.030 |
Why?
|
| Etanercept | 1 | 2012 | 4 | 0.030 |
Why?
|
| Adalimumab | 1 | 2012 | 5 | 0.030 |
Why?
|
| Infliximab | 1 | 2012 | 8 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2016 | 468 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2012 | 21 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 26 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 476 | 0.030 |
Why?
|
| Running | 1 | 2011 | 3 | 0.020 |
Why?
|
| Sexual Development | 1 | 2011 | 4 | 0.020 |
Why?
|
| Orchiectomy | 1 | 2011 | 6 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2012 | 327 | 0.020 |
Why?
|
| Smoking | 1 | 2014 | 494 | 0.020 |
Why?
|
| Algorithms | 1 | 2012 | 241 | 0.020 |
Why?
|
| Logistic Models | 1 | 2012 | 962 | 0.020 |
Why?
|
| Incidence | 1 | 2012 | 1314 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2012 | 1143 | 0.020 |
Why?
|
Concepts
(164)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(4)
People in Profiles who have published with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
-->